Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.
New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback